NCT06647277Not yet recruitingPhase 1
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
An Open-Label Phase I Clinical Trial of Vancomycin Followed by Fecal Microbiota Transplant for the Treatment of Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 8 Oct 2024
- Start date
- Jul 2027
- Primary completion date
- Dec 2027
- Lead sponsor
- ProgenaBiome
- Diseases
- Parkinson disease
- NCT number
- NCT06647277
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From Jul 2027 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Non-PD individuals
Who the study is looking for
- Individuals diagnosed with PD
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sabine Hazan Coordinator of this site? Confirm its status | Ventura | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.